The Pharmacy Times® Pharmacy Hospital Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to hospital and health-system pharmacists.
January 23rd 2025
The fast-track designation follows the FDA orphan drug designation that was granted for DYNE-101 in September 2023 for the same treatment population.
Expert: Considerations of SDOH Factors Should Be Integral to Pharmacy Practice, Education
October 26th 2023Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses SDOH and how pharmacists, particularly within community pharmacies, are the most accessible health care providers and can play a crucial role in advocating for patients.
Watch
Meeting the Challenges in Behavioral Health Care With Hybrid Pharmacy Approach
October 26th 2023The hybrid pharmacy model represents a significant step forward in providing the best possible care for individuals struggling with behavioral health conditions, ultimately improving their outcomes and overall well-being.
Read More
Why Data Point to Hospital At-Home Care as Next Evolution of Clinical Medicine
October 26th 2023With health systems undergoing a necessary reevaluation of how they allocate their funding into the future, initial data support the need for them to offer a hospital-at-home option for patients they serve.
Read More
Amivantamab With Lazertinib Can Reduce Risk of Disease Progression By 30% in Patients With NSCLC
October 25th 2023Compared to osimertinib alone, first-line treatment with amivantamab plus lazertinib was also shown to improve progression-free survival and have an increased duration of response.
Read More
Importance of Patient Navigation in Specialty Pharmacy
October 25th 2023Many patients face significant challenges in accessing their specialty medications, which highlights the importance of pharmacy-deployed patient navigation programs designed to help resolve nonclinical, system-related barriers to care.
Read More
Nivolumab Plus Chemotherapy Treatment Followed By Surgery Improved EFS in Patients With NSCLC
October 25th 2023Compared to placebo plus chemotherapy, nivolumab plus chemotherapy had also improved event-free survival and both pathological complete response and major pathologic response rates.
Read More
Lenacapavir Demonstrates Small Margin of Resistance for Those Heavily Treated With HIV
October 25th 2023Patients with HIV who were resistant to treatment with lenacapavir (Sunlenca; Gilead Sciences Inc) were found to have inadequate adherence to optimized background regimen or did not have a fully active antiretroviral.
Read More
Independent Rx Forum - NCPA Conference: Legal Update on PBM Litigation
October 24th 2023Jack Mozloom, vice president of Public Affairs at the National Community Pharmacists Association (NCPA), speaks with Matt Seiler, general counsel at NCPA, about the current PBM litigation at the 2023 NCPA Convention.
Listen
CDC Issues Alert to Address Shortage of RSV Treatment Nirsevimab
October 24th 2023Nirsevimab-alip (Beyfortus; Sanofi and AstraZeneca) is a monoclonal antibody approved to prevent against respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants under 8 months of age born during or entering their first RSV season.
Read More